171 related articles for article (PubMed ID: 29253854)
1. Human Neutrophil Peptide 1 as immunotherapeutic agent against Leishmania infected BALB/c mice.
Abdossamadi Z; Seyed N; Zahedifard F; Taheri T; Taslimi Y; Montakhab-Yeganeh H; Badirzadeh A; Vasei M; Gharibzadeh S; Rafati S
PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006123. PubMed ID: 29253854
[TBL] [Abstract][Full Text] [Related]
2. Live Leishmania tarentolae secreting HNP1 as an immunotherapeutic tool against Leishmania infection in BALB/c mice.
Abdossamadi Z; Taheri T; Seyed N; Montakhab-Yeganeh H; Zahedifard F; Taslimi Y; Habibzadeh S; Gholami E; Gharibzadeh S; Rafati S
Immunotherapy; 2017 Oct; 9(13):1089-1102. PubMed ID: 29032739
[TBL] [Abstract][Full Text] [Related]
3. Leishmania tarentolae expressing CXCL-10 as an efficient immunotherapy approach against Leishmania major-infected BALB/c mice.
Montakhab-Yeganeh H; Abdossamadi Z; Zahedifard F; Taslimi Y; Badirzadeh A; Saljoughian N; Taheri T; Taghikhani M; Rafati S
Parasite Immunol; 2017 Oct; 39(10):. PubMed ID: 28833211
[TBL] [Abstract][Full Text] [Related]
4. S-nitrosoglutathione (GSNO) is cytotoxic to intracellular amastigotes and promotes healing of topically treated Leishmania major or Leishmania braziliensis skin lesions.
Costa IS; de Souza GF; de Oliveira MG; Abrahamsohn Ide A
J Antimicrob Chemother; 2013 Nov; 68(11):2561-8. PubMed ID: 23788476
[TBL] [Abstract][Full Text] [Related]
5. EGFP reporter protein: its immunogenicity in Leishmania-infected BALB/c mice.
Seif S; Kazemi F; Gholami E; Seyed N; Taslimi Y; Habibzadeh S; Azarian B; Jamshidi S; Hashemi M; Rafati S; Taheri T
Appl Microbiol Biotechnol; 2016 May; 100(9):3923-34. PubMed ID: 26685673
[TBL] [Abstract][Full Text] [Related]
6. Antileishmanial activity of Urtica dioica extract against zoonotic cutaneous leishmaniasis.
Badirzadeh A; Heidari-Kharaji M; Fallah-Omrani V; Dabiri H; Araghi A; Salimi Chirani A
PLoS Negl Trop Dis; 2020 Jan; 14(1):e0007843. PubMed ID: 31929528
[TBL] [Abstract][Full Text] [Related]
7. Sambucus ebulus extract stimulates cellular responses in cutaneous leishmaniasis.
Heidari-Kharaji M; Fallah-Omrani V; Badirzadeh A; Mohammadi-Ghalehbin B; Nilforoushzadeh MA; Masoori L; Montakhab-Yeganeh H; Zare M
Parasite Immunol; 2019 Jan; 41(1):e12605. PubMed ID: 30472741
[TBL] [Abstract][Full Text] [Related]
8. Caffeic acid combined with autoclaved Leishmania major boosted the protection of infected BALB/c mice by enhancing IgG2 production, IFN-γ/TGF-β and iNO synthase/arginase1 ratios, and the death of infected phagocytes.
Belkhelfa-Slimani R; Djerdjouri B
Inflammopharmacology; 2018 Apr; 26(2):621-634. PubMed ID: 28988279
[TBL] [Abstract][Full Text] [Related]
9. Homeopathic medicines cause Th1 predominance and induce spleen and megakaryocytes changes in BALB/c mice infected with Leishmania infantum.
Cajueiro APB; Goma EP; Dos Santos HAM; Almeida Rodrigues I; Toma HK; Araújo SM; Bonamin LV; Gomes NBN; Castelo-Branco MTL; de Souza Dias EP; Dos Santos Pyrrho A; Holandino C
Cytokine; 2017 Jul; 95():97-101. PubMed ID: 28254560
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy induced by the oral administration of Agaricus blazei Murill against Leishmania amazonensis.
Valadares DG; Duarte MC; Ramírez L; Chávez-Fumagalli MA; Lage PS; Martins VT; Costa LE; Ribeiro TG; Régis WC; Soto M; Fernandes AP; Tavares CA; Coelho EA
Parasitol Res; 2012 Oct; 111(4):1807-16. PubMed ID: 22797606
[TBL] [Abstract][Full Text] [Related]
11. Arginase activity in pathogenic and non-pathogenic species of Leishmania parasites.
Badirzadeh A; Taheri T; Taslimi Y; Abdossamadi Z; Heidari-Kharaji M; Gholami E; Sedaghat B; Niyyati M; Rafati S
PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005774. PubMed ID: 28708893
[TBL] [Abstract][Full Text] [Related]
12. Treatment with synthetic lipophilic tyrosyl ester controls Leishmania major infection by reducing parasite load in BALB/c mice.
Sghaier RM; Aissa I; Attia H; Bali A; Leon Martinez PA; Mkannez G; Guerfali FZ; Gargouri Y; Laouini D
Parasitology; 2016 Oct; 143(12):1615-21. PubMed ID: 27312247
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the long-term and short-term protection in mouse model of Leishmania major infection following vaccination with Live Iranian Lizard Leishmania mixed with chitin microparticles.
Noroozbeygi M; Keshavarzian N; Haji Molla Hoseini M; Haghdoust S; Yeganeh F
Parasite Immunol; 2024 Jan; 46(1):e13018. PubMed ID: 37987175
[TBL] [Abstract][Full Text] [Related]
14. Leishmanicidal potentials of
Sharifi F; Sharififar F; Pournamdari M; Ansari M; Tavakoli Oliaee R; Bamorovat M; Khosravi A; Keyhani AR; Salarkia E; Mortazaeizdeh A; Dabiri S; Khamesipour A; Sharifi I
J Med Microbiol; 2021 Jun; 70(6):. PubMed ID: 34115583
[No Abstract] [Full Text] [Related]
15. Skin-derived macrophages from Leishmania major-susceptible mice exhibit interleukin-12- and interferon-gamma-independent nitric oxide production and parasite killing after treatment with immunostimulatory DNA.
von Stebut E; Belkaid Y; Nguyen B; Wilson M; Sacks DL; Udey MC
J Invest Dermatol; 2002 Sep; 119(3):621-8. PubMed ID: 12230504
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen is effective in the treatment of Leishmania amazonensis infections in mice.
Miguel DC; Yokoyama-Yasunaka JK; Uliana SR
PLoS Negl Trop Dis; 2008 Jun; 2(6):e249. PubMed ID: 18545685
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapeutic effects of chitin in comparison with chitosan against Leishmania major infection.
Hoseini MH; Moradi M; Alimohammadian MH; Shahgoli VK; Darabi H; Rostami A
Parasitol Int; 2016 Apr; 65(2):99-104. PubMed ID: 26518128
[TBL] [Abstract][Full Text] [Related]
18. The involvement of neutrophils in the resistance to Leishmania major infection in susceptible but not in resistant mice.
Chen L; Zhang ZH; Watanabe T; Yamashita T; Kobayakawa T; Kaneko A; Fujiwara H; Sendo F
Parasitol Int; 2005 Jun; 54(2):109-18. PubMed ID: 15866472
[TBL] [Abstract][Full Text] [Related]
19. Ferroportin-encapsulated nanoparticles reduce infection and improve immunity in mice infected with Leishmania major.
Rafiee A; Riazi-Rad F; Darabi H; Khaze V; Javadian S; Ajdary S; Bahrami F; Alimohammadian MH
Int J Pharm; 2014 May; 466(1-2):375-81. PubMed ID: 24657288
[TBL] [Abstract][Full Text] [Related]
20. In Vitro Infectivity Assessment by Drug Susceptibility Comparison of Recombinant Leishmania major Expressing Enhanced Green Fluorescent Protein or EGFP-Luciferase Fused Genes with Wild-Type Parasite.
Sadeghi S; Seyed N; Etemadzadeh MH; Abediankenari S; Rafati S; Taheri T
Korean J Parasitol; 2015 Aug; 53(4):385-94. PubMed ID: 26323836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
